手机购彩

Technological innovation

Hengrui insists on "scientific and technological innovation" as the company's primary strategy for development, and has formed an independent and complete innovation system with a clear division of labor and unified collaboration, which has laid a solid foundation for new drug research and development.

Learn more

Human Resources

The company always adheres to the development concept of "talent is the first resource", continuously introduces high-level talents at home and abroad, gives full play to the leading role of high-end talents, makes every effort to build a talented height, and promotes the innovation and development of enterprises.

Learn more

company culture

Hengrui Medicine, while developing rapidly and achieving economic benefits, adheres to the people-oriented principle, gives back to the society, and actively participates in social welfare activities in various forms.

Learn more

Quality Brand

The company focuses on academic communication and market promotion, and has established a marketing network throughout the country, forming a professional, standardized and orderly perfect market system to provide patients with more professional and accurate services.

Learn more

Charitable activities

Leadership care

  • Heavy | Hengrui Medicine Capecitabine Tablets Pass Consistency Evaluation

    Recently, Hengrui Medicine received the "Approval for Supplementary Drug Application" approved by the State Drug Administration, and approved the company's capecitabine to pass the consistency evaluation of the quality and efficacy of generic drugs. Capecitabine is a 5-fluorouracil prodrug that can be converted into 5-fluorouracil in vivo by high concentrations of thymidine phosphorylase (TP) in tumor tissues, inhibiting DNA and RNA synthesis, and exerting anti-tumor effects ...

  • Hengrui Pharmaceutical's innovative drug SHR0302 tablets approved for clinical use

    Recently, Ruishi Biopharmaceutical Co., Ltd., a subsidiary of Hengrui Medicine, received the "Clinical Trial Notification" approved by the State Drug Administration, and approved the company's innovative drug SHR0302 to carry out clinical trials intended for alopecia areata. Alopecia areata is a type of non-scarring alopecia, which often occurs in the hairy parts of the body. The local skin is normal and there are no conscious symptoms. It is the second highest incidence of hair loss worldwide. At home and abroad ...

  • Hengrui Pharmaceutical's 1.1 innovative drug Apatinib was declared for listing in advanced liver cancer

    A few days ago, Hengrui Pharmaceutical's 1.1 innovative drug apatinib mesylate was used for the treatment of marketing applications for advanced hepatocellular carcinoma that failed or was intolerable after receiving at least first-line systemic treatment, and was accepted by the State Food and Drug Administration. Apatinib mesylate is a national class 1.1 innovative drug with independent intellectual property rights developed by Hengrui Medicine for 10 years. In 2014, the indications for the treatment of advanced gastric cancer were approved and marketed. It is the world's first ...

  • Xiangyun Long, Secretary of the Lianyungang Municipal Party Committee, and his party investigated the production of Hengrui Pharmaceutical's anti-epidemic drugs

    On the morning of January 30, Xiangyun Long, secretary of the Lianyungang Municipal Party Committee and director of the Standing Committee of the Municipal People's Congress, went to Hengrui Pharmaceutical to investigate the company's production of anti-epidemic drugs and measures to prevent new coronavirus among employees. City leaders Liu Haitao, Yin Zheqiang, and Huang Yuanzheng participated in the investigation. Jiang Sumei, deputy general manager of Hengrui Medicine, and others received the survey. Secretary Xiang and his entourage made a detailed understanding of the company's anti-epidemic drugs in Hengrui Pharmaceutical New Pharmaceutical Industrial Park ...